WallStreetZenWallStreetZen

NASDAQ: DRRX
Durect Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for DRRX

Based on 1 analyst offering 12 month price targets for Durect Corp.
Min Forecast
$5.00+233.33%
Avg Forecast
$5.00+233.33%
Max Forecast
$5.00+233.33%

Should I buy or sell DRRX stock?

Based on 1 analyst offering ratings for Durect Corp.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DRRX stock forecasts and price targets.

DRRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-01

1 of 1

Forecast return on equity

Is DRRX forecast to generate an efficient return?
Company
-240.33%
Industry
37.1%
Market
58.16%
DRRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DRRX forecast to generate an efficient return on assets?
Company
-40.55%
Industry
15.92%
DRRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DRRX earnings per share forecast

What is DRRX's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.80
Avg 2 year Forecast
-$1.32
Avg 3 year Forecast
-$1.17

DRRX revenue forecast

What is DRRX's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$8.0M-5.1%
Avg 2 year Forecast
$8.6M+1.89%
Avg 3 year Forecast
$23.2M+175.35%
DRRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DRRX revenue growth forecast

How is DRRX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
34.65%
Industry
6.42%
Market
9.32%
DRRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DRRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DRRX vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
DRRX$1.50$5.00+233.33%Buy
BGM$6.30N/AN/A
EGRX$3.83N/AN/A
SCYX$1.37N/AN/A
BGXX$0.19N/AN/A
View Top Pharmaceutical Stocks

Durect Stock Forecast FAQ

Is Durect Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: DRRX) stock is to Buy DRRX stock.

Out of 1 analyst, 0 (0%) are recommending DRRX as a Strong Buy, 1 (100%) are recommending DRRX as a Buy, 0 (0%) are recommending DRRX as a Hold, 0 (0%) are recommending DRRX as a Sell, and 0 (0%) are recommending DRRX as a Strong Sell.

If you're new to stock investing, here's how to buy Durect stock.

What is DRRX's earnings growth forecast for 2024-2026?

(NASDAQ: DRRX) Durect's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 21.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.98%.

Durect's earnings in 2024 is -$15,799,000.On average, 3 Wall Street analysts forecast DRRX's earnings for 2024 to be -$24,933,935, with the lowest DRRX earnings forecast at -$33,212,138, and the highest DRRX earnings forecast at -$20,796,385. On average, 1 Wall Street analyst forecast DRRX's earnings for 2025 to be -$40,971,983, with the lowest DRRX earnings forecast at -$40,971,983, and the highest DRRX earnings forecast at -$40,971,983.

In 2026, DRRX is forecast to generate -$36,316,076 in earnings, with the lowest earnings forecast at -$36,316,076 and the highest earnings forecast at -$36,316,076.

What is DRRX's revenue growth forecast for 2024-2026?

(NASDAQ: DRRX) Durect's forecast annual revenue growth rate of 34.65% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.32%.

Durect's revenue in 2024 is $8,411,000.On average, 3 Wall Street analysts forecast DRRX's revenue for 2024 to be $247,756,339, with the lowest DRRX revenue forecast at $242,045,093, and the highest DRRX revenue forecast at $258,247,650. On average, 1 Wall Street analysts forecast DRRX's revenue for 2025 to be $266,007,495, with the lowest DRRX revenue forecast at $266,007,495, and the highest DRRX revenue forecast at $266,007,495.

In 2026, DRRX is forecast to generate $718,872,064 in revenue, with the lowest revenue forecast at $718,872,064 and the highest revenue forecast at $718,872,064.

What is DRRX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: DRRX) forecast ROA is -40.55%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 15.92%.

What is DRRX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year DRRX price target, the average DRRX price target is $5.00, with the highest DRRX stock price forecast at $5.00 and the lowest DRRX stock price forecast at $5.00.

The Wall Street analyst predicted that Durect's share price could reach $5.00 by Apr 1, 2025. The average Durect stock price prediction forecasts a potential upside of 233.33% from the current DRRX share price of $1.50.

What is DRRX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: DRRX) Durect's current Earnings Per Share (EPS) is -$0.49. On average, analysts forecast that DRRX's EPS will be -$0.80 for 2024, with the lowest EPS forecast at -$1.07, and the highest EPS forecast at -$0.67. On average, analysts forecast that DRRX's EPS will be -$1.32 for 2025, with the lowest EPS forecast at -$1.32, and the highest EPS forecast at -$1.32. In 2026, DRRX's EPS is forecast to hit -$1.17 (min: -$1.17, max: -$1.17).

What is DRRX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: DRRX) forecast ROE is -240.33%, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.